GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achilles Therapeutics PLC (NAS:ACHL) » Definitions » Capex-to-Operating-Cash-Flow

Achilles Therapeutics (Achilles Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Achilles Therapeutics Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Achilles Therapeutics's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Achilles Therapeutics Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Achilles Therapeutics's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achilles Therapeutics Capex-to-Operating-Cash-Flow Chart

Achilles Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
- - - - -

Achilles Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Achilles Therapeutics's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Achilles Therapeutics's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achilles Therapeutics's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achilles Therapeutics's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Achilles Therapeutics's Capex-to-Operating-Cash-Flow falls into.



Achilles Therapeutics Capex-to-Operating-Cash-Flow Calculation

Achilles Therapeutics's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.1) / -48.449
=N/A

Achilles Therapeutics's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achilles Therapeutics  (NAS:ACHL) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Achilles Therapeutics Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Achilles Therapeutics's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Achilles Therapeutics (Achilles Therapeutics) Business Description

Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics (Achilles Therapeutics) Headlines

From GuruFocus

Achilles Therapeutics to Present at Upcoming Conferences

By sperokesalga sperokesalga 06-12-2023

Achilles Therapeutics Recognized with the 2022 PING Innovation Award

By GuruFocusNews GuruFocusNews 07-01-2022